Huntington Bancshares Inc logo

HU3 - Huntington Bancshares Inc News Story

€8.2 0.0  0.0%

Last Trade - 18/09/20

Sector
Financials
Size
Large Cap
Market Cap £7.68bn
Enterprise Value £15.63bn
Revenue £3.60bn
Position in Universe 117th / 1039

U.S. RESEARCH ROUNDUP- Cabot, Eagle Bancorp, Xylem

Mon 27th July, 2020 8:19am
July 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Cabot, Eagle Bancorp and Xylem, on Monday. 
    
    HIGHLIGHTS
     * Cabot Corp  CBT.N : JP Morgan cuts to neutral from overweight
     * Eagle Bancorp  EGBN.O : Piper Sandler resumes with neutral rating and $35 price target
     * Xylem Inc  XYL.N : Jefferies raises target price to $75 from $70
        
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order. 
    
     * 1St Constitution Bancorp  FCCY.O : Piper Sandler raises target price to $13.50 from $13
     * 1St Source Corp  SRCE.O : Piper Sandler raises target price to $43 from $42
     * American Express Co  AXP.N : Evercore ISI raises target price to $91 from $76
     * Ardagh Group SA  ARD.N : RBC raises target price to $18 from $17
     * Atlantic Capital Bancshares Inc  ACBI.O : SunTrust Robinson cuts PT to $12 from $14
     * Avantor Inc  AVTR.N : Jefferies raises target price to $23 from $21
     * Bank Ozk  OZK.O : SunTrust Robinson raises target price to $26 from $25
     * Bio Rad Laboratories Inc  BIO.N : Jefferies raises target price to $600 from $525
     * Byline Bancorp Inc  BY.N : Piper Sandler raises target price to $16 from $15
     * Cabot Corp  CBT.N : JP Morgan cuts to neutral from overweight
     * Cabot Corp  CBT.N : JP Morgan raises price target to $38 from $33
     * Cognex Corp  CGNX.O : JP Morgan raises target price to $44 from $40
     * Corbus Pharmaceuticals Holdings Inc  CRBP.O : Jefferies raises PT to $18 from $17
     * Core Laboratories NV  CLB.N : Simmons Energy raises target price to $16 from $15
     * Dun & Bradstreet Holdings Inc  DNB.N : JP Morgan initiates coverage with neutral rating  
     * Dun & Bradstreet Holdings Inc  DNB.N : JP Morgan initiates coverage with PT of $24
     * Eagle Bancorp  EGBN.O : Piper Sandler resumes with neutral rating and $35 price target
     * Encompass Health Corp  EHC.N : Jefferies cuts target price to $86 from $90
     * Energy Transfer LP  ET.N : RBC cuts target price to $10 from $11
     * Esquire Financial Holdings Inc  ESQ.O : Piper Sandler raises target price to $19 from $18
     * Exelon Corp  EXC.O : Credit Suisse raises target price to $46 from $45
     * F5 Networks Inc  FFIV.O : RBC raises target price to $154 from $135
     * First Financial Bancorp  FFBC.O : RBC raises target price to $15 from $14
     * Fulgent Genetics Inc  FLGT.O : Piper Sandler raises target price to $31 from $21
     * Gentex Corp  GNTX.O : Jefferies raises target price to $32 from $31
     * Graco Inc  GGG.N : Jefferies raises target price to $55 from $50
     * Honeywell  HON.N : Cowen and Company raises target price to $160 from $155
     * Honeywell  HON.N : Jefferies raises target price to $175 from $170
     * Honeywell  HON.N : RBC cuts target price to $166 from $167
     * Huntington Bancshares Inc  HBAN.O : JP Morgan raises target price to $10 from $9
     * Huntington Bancshares Inc  HBAN.O : Wedbush raises target price to $10 from $9
     * IAC/InterActiveCorp  IAC.O : Jefferies raises target price to $155 from $150
     * I-Mab  IMAB.O : Cantor Fitzgerald initiates with overweight rating and price target of $50
     * Immunomedics Inc  IMMU.O : Jefferies raises target price to $55 from $41
     * Keurig DR Pepper Inc  KDP.N : Jefferies raises target price to $39 from $36
     * Keurig DR Pepper Inc  KDP.N : JP Morgan raises price target to $31 from $29
     * Metropolitan Bank Holding Corp  MCB.N : JP Morgan raises target price to $37 from $35
     * Midland States Bancorp Inc  MSBI.O : Piper Sandler raises target price to $16 from $15.50
     * Moog Inc  MOGa.N : Canaccord Genuity raises target price to $60 from $56
     * Nextera Energy Inc  NEE.N : Credit Suisse raises target price to $266 from $265
     * Nextera Energy Inc  NEE.N : Evercore ISI raises target price to $277 from $249
     * Old Dominion Freight Line Inc  ODFL.O : Baird raises target price to $180 from $140
     * Orasure Technologies Inc  OSUR.O : Jefferies raises target price to $16 from $15
     * P&G  PG.N : Jefferies raises target price to $148 from $140
     * Pentair Plc  PNR.N : Jefferies raises target price to $45 from $40
     * People'S United Financial Inc  PBCT.O : JP Morgan raises PT to $12.50 from $11.50
     * Perkinelmer Inc  PKI.N : Jefferies raises target price to $110 from $96
     * Robert Half International Inc  RHI.N : RBC raises target price to $54 from $51
     * Sailpoint Technologies Holdings Inc  SAIL.N : RBC raises target price to $35 from $30
     * Schlumberger NV  SLB.N : Atb Capital Markets raises target price to $27 from $26
     * Schlumberger NV  SLB.N : JP Morgan raises price target to $19 from $17
     * Schlumberger NV  SLB.N : Wells Fargo raises target price to $25 from $23
     * TRI Pointe Group Inc  TPH.N : Evercore ISI raises target price to $25 from $24
     * Umpqua Holdings Corp  UMPQ.O : JP Morgan raises target price to $11.50 from $10.50
     * Valley National Bancorp  VLY.O : JP Morgan raises target price to $8 from $7.50
     * Verizon  VZ.N : JP Morgan Establishes Dec 2021 PT of $60 vs dec 2020 price target of $61
     * Virtus Investment Partners Inc  VRTS.O : Piper Sandler raises PT to $185 from $150
     * Vornado Realty Trust  VNO.N : Evercore ISI cuts target price to $44 from $45
     * Washington Federal Inc  WAFD.O : Piper Sandler raises target price to $25.50 from $25
     * Waters Corp  WAT.N : Jefferies raises target price to $215 from $195
     * Xylem Inc  XYL.N : Jefferies raises target price to $75 from $70
 

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.